| 高国娟,翁娅韵.复方鲜竹沥液联合布地奈德和孟鲁司特钠治疗咳嗽性哮喘的临床疗效及对炎症因子和肺功能的影响[J].浙江中西医结合杂志,2019,29(1): |
| 复方鲜竹沥液联合布地奈德和孟鲁司特钠治疗咳嗽性哮喘的临床疗效及对炎症因子和肺功能的影响 |
| Curative effect and influence of compound Xianzhuli Liqulid combined with budesonide and montelukast sodium on inflammatory factor and lung function in treatment of patients with cough variant asthma |
| 投稿时间：2018-02-06 修订日期：2019-01-07 |
| DOI： |
| 中文关键词: 咳嗽性哮喘 复方鲜竹沥液 布地奈德 孟鲁司特钠 炎症因子 肺功能 |
| 英文关键词:cough variant asthma compound Xianzhuli Liqulid budesonide montelukast sodium inflammation factors lung function |
| 基金项目: |
|
| 摘要点击次数: 1188 |
| 全文下载次数: 11 |
| 中文摘要: |
| 目的 探讨复方鲜竹沥液联合布地奈德和孟鲁司特钠治疗咳嗽性哮喘的临床疗效及对炎症因子和肺功能的影响。方法 选择2015年9月至2016年9月本院收治的124例咳嗽性哮喘为对象，按照随机数字表法分为对照组和观察组，每组62例。对照组给予布地奈德和孟鲁司特钠治疗，观察组给予复方鲜竹沥液联合布地奈德和孟鲁司特钠治疗，共治疗8周。观察患者的临床疗效，药物不良反应和复发率，比较治疗前后两组炎症因子[白细胞介素-8（IL-8）、转化生长因子β1（TGF-β1），肿瘤坏死因子-α（TNF-α）和免疫球蛋白 E（IgE）]，肺功能指标[第1秒用力呼气容积 (FEV1)占预计值的百分比（FEV1%pred）、FEV1与用力肺活量比值（FEV1/FVC）、呼气峰流速占预计值的百分比（PEF%pred）]水平。结果 治疗后观察组总有效率96.77%高于对照组82.26%（P<0.05）；治疗前两组IL-8、TGF-β1、TNF-α和IgE比较（P>0.05），治疗后观察组IL-8、TNF-α和IgE水平低于对照组，TGF-β1水平高于对照组（P<0.05）；治疗前两组FEV1%pred、FEV1/FVC、PEF%pred比较（P>0.05），治疗后观察组FEV1%pred、FEV1/FVC、PEF%pred高于对照组（P<0.05）；两组不良反应为胃肠道反应、头晕、嗜睡、恶心、皮疹，观察组和对照组的药物不良反应发生率分别为23.26%和18.60%（P>0.05），随访1年观察组的复发率4.84%低于对照组17.74%（P<0.05）。结论 复方鲜竹沥液联合布地奈德和孟鲁司特钠治疗咳嗽性哮喘临床疗效显著，可降低炎症因子水平，提高肺功能，减少复发率，且安全性较好。 |
| 英文摘要: |
| objective to investigate the curative effect and influence of compound Xianzhuli Liqulid combined with budesonide and montelukast sodium on inflammatory factor and lung function in treatment of patients with cough variant asthma. Method One hundred and twenty-four patients with cough variant asthma were selected as object between September 2015 and September 2016 in our hospital, and were divided into control group and Observation group according to the random number table method, 62 cases in each group. The control group was given budesonide and montelukast sodium therapy, the Observation group was given compound Xianzhuli Liqulid combined with budesonide and montelukast sodium for eight weeks. The clinical curative effect, adverse drug reactions and the recurrence rate were observed. The inflammatory factor of interleukin 8 (IL-8), transforming growth factor β1 (TGF - beta 1), tumor necrosis factorα(TNF-α) and immunoglobulin E (IgE), pulmonary function index: the percentage of forced expiratory volume in the first second (FEV1%pred), the ratio of forced expiratory volume to forced vital capacity (FEV1/FVC) in the first second, and the percentage of peak expiratory flow rate (PEF%pred) were estimated. were compared in before and after the treatment. Results The total effective rate 96.77% in Observation group was higher than the control group 82.26% (P < 0.05); Before treatment the levels of IL-8, TGF-β1, TNF-α and IgE were no difference (P>0.05), and after treatment the levels of IL-8, TNF-α and IgE in Observation group were lower than the control group, and the TGF-β1 was higher than the control group (P<0.05); Before treatment the FEV1%pred、FEV1/FVC、PEF%pred were no difference (P>0.05), and after treatment the FEV1%pred、FEV1/FVC、PEF%pred in Observation group were higher than the control group (P<0.05);The main adverse reaction were gastrointestinal reaction, dizziness, drowsiness, nausea, rashes, and the incidence of adverse drug reactions in Observation group 23.26% and control group 18.60% were no difference (P>0.05), After 1 year follow-up research the recurrence rate in Observation group 4.84% was lower than the control group17.74% (P<0.05). Conclusion The compound Xianzhuli Liqulid combined with budesonide and montelukast sodium in treatment of patients with cough variant asthma have better clinical curative effect, can reduce inflammatory factor levels, improve lung function, reduce the recurrence rate, and have better security. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
